



1st Cambodian National Medical Laboratory Quality Conference June 11-12, 2019

Analytical systems: Cambodian scenario

Ong Siew Kim MAACB, FAACB, MBA, PBT(ASCPi), EdD Project Coordinator

E: siewkimong@itech-cambodia.org



- Laboratory Processes
- Snapshot of analytical systems in laboratories
- Define good laboratory quality

Laboratory processes

Pre-analytical phase -Test request -Blood collected

> Analytical phase -Specimen quality -Analysis, IQC -Equipment

Post-Analytical phase

- Clinician see result

3

- Clinical decision
- Turnaround (TAT)

Snapshot of analytical systems in laboratories

Hematology analyzers

Analzyer	Lab 1	Lab 2	Lab 3	Lab 4	Lab 5	Lab 6	Lab 7	Lab 8	Lab 9
SYSMEX-KX21				\checkmark				\checkmark	
SYSMEX-XP100	\checkmark	\checkmark		\checkmark			\checkmark	\checkmark	
SYSMEX-Xs500i									
SYSMEX-Xn550									
ABX Miros ES 60 (Horiba)							\checkmark		
BC-3000Plus (Mindray)							\checkmark		
Medonic M32 (Sweden)		\checkmark							

Biochemistry analyzers

Analzyer	Lab 1	Lab 2	Lab 3	Lab 4	Lab 5	Lab 6	Lab 7	Lab 8	Lab 9
Stat Fax 3300 (USA)	V			V					
Pentra C400 (Horiba)			$\sqrt{\sqrt{1}}$						
Pentra C-200 (Horiba)									$\sqrt{}$
Humalyzer 3000									
Express Plus Bayer					$\sqrt{\sqrt{1}}$				
Mindray BA-88A		V							
Humanlyzer primus						\checkmark			

Examples of analyzers in laboratory



Parameter		
Accuracy		
Reliability		
Timeliness of results		

Parameter	Operation level	Clinical Decision	ISO 15189
Accuracy	Correlation studies	Diagnosis	4.13 Control of records 5.6.4 Comparability of examination results
Reliability			
Timeliness of results			

Parameter	Operation level	Clinical Decision	ISO 15189
Accuracy	Correlation studies	Diagnosis	4.13 Control of records 5.6.4 Comparability of examination results
Reliability	Precision (CV%)	 Monitoring (Repeat visits) Prognosis 	5.3.2.7 Reagents and consumables records
Timeliness of results			

Parameter	Operation level	Clinical Decision	ISO 15189
Accuracy	Correlation studies	Diagnosis	4.13 Control of records 5.6.4 Comparability of examination results
Reliability	Precision (CV%)	 Monitoring (Repeat visits) Prognosis 	5.3.2.7 Reagents and consumables records
Timeliness of results	Turn-around time (TAT) Example SOP: Contingency plan	Appropriate treatment	4.1.2.1 Managementcommitmentuninterrupted testingservices

Different types of analyer: What are critical factors on quality and cost?

Different Analyzer	Correlation studies	Impact on quality	Impact on cost
1	NA	-Good contingency plan -Communication record	-Sufficient for small laboratory -TAT may be prolonged
2+	Yes	 -Record on reagents & consumables -Correlation studies documentation -IQC for each analyzer 	 -Keeping different sets of reagents/consumables -Staff training & competency -Cost of reagents for comparison studies -Management of IQC (increase staff time and cost of QC materials)

Different reagents, different vendors

Example: Lab 7; Biochemistry; Mindray BA-88A

Tests	Reagents vendors	
Glucose, Triglycerides,	Human	
Cholesterol, Creatinine,	Analyticon Cypress	
Transaminases, Total protein		

Different reagents: What is the impact on quality and cost?

	Impact on quality		Impact on cost
•	Record on reagents & consumables	•	Keeping different sets of reagents/consumables Time on staff training & competency
•	Correlation studies for reagents documentation	•	Cost of reagents and time for comparison studies
•	IQC for each reagents	•	Management of IQC (increase staff time and cost of QC materials)



Summary on quality management

Proposal	Operational activity	Impact
Similar model analyzer	Minimize variables such imprecision CV%.	Clinical decision on patients monitoring.
Quality control with appropriate ranges for test	Reduce number of QC runs to establish the range.	Reduce QC cost and wastage.
Reagents from same manufacturer	Reduce reagent verification studies and correlation.	Reduce reagent cost, wastage and error.





Bureau of Medical Laboratory Services, Department of Hospital Services,
 Ministry of Health, Cambodia

✓ Staff of 12 laboratories mentored by I-TECH

✓ Defense Threat Reduction Agency funding

